Topline results from the Phase 2b/3 RESTORE trial showed high- and low-dose MCO-010 optogenetic therapy significantly improved best-corrected visual acuity (BCVA) in patients with retinitis pigmentosa. These data were presented at the American Society of Retina Specialists (ASRS) 42nd Annual Meeting.
OCU400 has previously been evaluated in a phase 1/2 trial, data from which suggests positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (MLMT), and Low-Luminance Visual Acuity (LLVA) among treated eyes. In this study, most patients (89%; n = 16/18) demonstrated preservation or improvement in the treated eye either on BCVA or LLVA or MLMT scores from baseline. Most (78%; n = 18) also had preservation or improvement in treated eyes in MLMT scores from baseline.
Kiora Pharmaceuticals, Inc. recently shared additional data from their ABACUS-1 clinical trial for KIO-301, a small molecule photoswitch aimed at improving vision in patients with late-stage retinitis pigmentosa. The new findings highlight a significant increase in brain activity in the visual cortex as measured by functional MRI (fMRI), confirming the drug's potential in enhancing visual processing.
"Ocugen Inc announced the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP)....89% (16/18) of RP patients demonstrated preservation or improvement in the treated eye."
A gene agnostic treatment for RP enters a phase 3 clinical trial.
"Results from RESTORE, the first randomized, controlled trial of mutation-agnostic gene therapy for a genetic disease, demonstrated clinically meaningful improvement in best-corrected visual acuity (BCVA) with MCO-010 in legally blind individuals with neurodegeneration of the retina.
"Based on these positive results, Nanoscope Therapeutics has announced its intention to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in the second half of 2024, as the first step in its global regulatory and commercialization strategy."
A team of researchers has recently made an incredible breakthrough towards reversing incurable eye diseases.
The researchers are working to create solar-powered eye implants. This new technology revolves around powering sensors and cameras in the eye by using solar photovoltaic panels, according to New Atlas.
This could lead to new solutions that help improve the lives of people with vision-related diseases like retinitis pigmentosa and age-related macular degeneration. Neither of these diseases has a cure and both of them affect the parts of the eye that helps you register images.
A team of researchers from Yonsei University, Severance Hospital, and Gangnam Severance Hospital has developed a high-safety, liquid metal-based soft artificial retina.
This innovative technology promises to restore vision to patients blinded by retinal diseases, including retinitis pigmentosa and macular degeneration.
“We observed significant vision restoration in many patients with severe vision loss, including those who were completely blind,” David Boyer, M.D., an investigator in the trial and ophthalmology professor at the University of Southern California Keck School of Medicine, said in a March 26 release. “Many patients treated with MCO-010 derived a clinically meaningful benefit measurable on the primary visual function test, and this effect was confirmed by a parallel improvement in functional vision assessments.”
"For the first time, the team utilized a substance that inhibits the inflammatory factor EZH2, which contributes to retinal degeneration, along with an anti-inflammatory agent. When mice with retinal degeneration were injected with the anti-inflammatory drug, the progression of retinal degeneration slowed down."
